Xiaojuan Li - Sinopharm Group Chief Officer

All Insiders Germany . 
Stock . Sinopharm Group Co . Stakeholders . Insider . Xiaojuan Li
X2S Stock  EUR 2.51  0.01  0.40%   

Insider

Xiaojuan Li is Chief Officer of Sinopharm Group Co
Age 47
Phone86 21 2305 2666
Webhttps://www.sinopharmgroup.com.cn

Sinopharm Group Management Efficiency

The company has return on total asset (ROA) of 0.0364 % which means that it generated a profit of $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1319 %, meaning that it generated $0.1319 on every $100 dollars invested by stockholders. Sinopharm Group's management efficiency ratios could be used to measure how well Sinopharm Group manages its routine affairs as well as how well it operates its assets and liabilities.
Sinopharm Group Co has accumulated 8.42 B in total debt with debt to equity ratio (D/E) of 0.93, which is about average as compared to similar companies. Sinopharm Group has a current ratio of 1.26, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist Sinopharm Group until it has trouble settling it off, either with new capital or with free cash flow. So, Sinopharm Group's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sinopharm Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sinopharm to invest in growth at high rates of return. When we think about Sinopharm Group's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 10 records

INSIDER Age

Matthew EMBACommonwealth Bank of
47
Mike VacyLyleCommonwealth Bank of
N/A
Sian LewisCommonwealth Bank of
N/A
Sinead TaylorCommonwealth Bank of
N/A
Nigel WilliamsCommonwealth Bank of
N/A
Gavin MunroeCommonwealth Bank of
N/A
LLB BACommonwealth Bank of
N/A
Melanie KirkCommonwealth Bank of
N/A
CA BMSCommonwealth Bank of
N/A
Alan DochertyCommonwealth Bank of
N/A
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GRP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people. Sinopharm Group Co (X2S) is traded on Frankfurt Exchange in Germany and employs 113,234 people.

Management Performance

Return On Equity0.13
Return On Asset0.0364

Sinopharm Group Leadership Team

Elected by the shareholders, the Sinopharm Group's board of directors comprises two types of representatives: Sinopharm Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinopharm. The board's role is to monitor Sinopharm Group's management team and ensure that shareholders' interests are well served. Sinopharm Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinopharm Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
Yijian Wu, Company Board
Xiaojuan Li, Chief Officer
Qingming Yu, Ex Chairman
Yong Liu, Pres Director
Shuangjun Xu, NonEx VP
Xiuchang Jiang, CFO VP
Wanyong Lian, VP
Maisong Cai, VP

Sinopharm Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sinopharm Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.13
Return On Asset0.0364
Profit Margin0.01 %
Operating Margin0.04 %
Current Valuation15.96 B
Shares Outstanding1.34 B
Shares Owned By Insiders0.01 %
Shares Owned By Institutions50.99 %
Price To Earning6.10 X
Price To Book0.89 X

Currently Active Assets on Macroaxis

VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
MSFTMicrosoft
GMGeneral Motors

Other Information on Investing in Sinopharm Stock

Sinopharm Group financial ratios help investors to determine whether Sinopharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinopharm with respect to the benefits of owning Sinopharm Group security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY